STAT+: FDA offers new details on quicker approval pathway for personalized gene therapies

The Food and Drug Administration has released new details outlining an expedited regulatory pathway for individualized and customized gene therapies. The initiative is designed to address the unique clinical trial and manufacturing challenges inherent to developing treatments for ultra-rare patient populations. Rare disease advocacy groups have welcomed the guidance as a vital step toward reducing administrative delays for life-saving genetic interventions.